206 related articles for article (PubMed ID: 22683936)
1. The impact of surface- and nano-crystallisation on the detected amorphous content and the dissolution behaviour of amorphous indomethacin.
Priemel PA; Grohganz H; Gordon KC; Rades T; Strachan CJ
Eur J Pharm Biopharm; 2012 Sep; 82(1):187-93. PubMed ID: 22683936
[TBL] [Abstract][Full Text] [Related]
2. Investigation of properties and recrystallisation behaviour of amorphous indomethacin samples prepared by different methods.
Karmwar P; Graeser K; Gordon KC; Strachan CJ; Rades T
Int J Pharm; 2011 Sep; 417(1-2):94-100. PubMed ID: 21182910
[TBL] [Abstract][Full Text] [Related]
3. Crystallization of amorphous indomethacin during dissolution: effect of processing and annealing.
Greco K; Bogner R
Mol Pharm; 2010 Oct; 7(5):1406-18. PubMed ID: 20459092
[TBL] [Abstract][Full Text] [Related]
4. Coamorphous drug systems: enhanced physical stability and dissolution rate of indomethacin and naproxen.
Löbmann K; Laitinen R; Grohganz H; Gordon KC; Strachan C; Rades T
Mol Pharm; 2011 Oct; 8(5):1919-28. PubMed ID: 21815614
[TBL] [Abstract][Full Text] [Related]
5. Effect of different preparation methods on the dissolution behaviour of amorphous indomethacin.
Karmwar P; Graeser K; Gordon KC; Strachan CJ; Rades T
Eur J Pharm Biopharm; 2012 Feb; 80(2):459-64. PubMed ID: 22019529
[TBL] [Abstract][Full Text] [Related]
6. In situ amorphisation of indomethacin with Eudragit® E during dissolution.
Priemel PA; Laitinen R; Grohganz H; Rades T; Strachan CJ
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1259-65. PubMed ID: 24056054
[TBL] [Abstract][Full Text] [Related]
7. Preparation and characterization of co-amorphous Ritonavir-Indomethacin systems by solvent evaporation technique: improved dissolution behavior and physical stability without evidence of intermolecular interactions.
Dengale SJ; Ranjan OP; Hussen SS; Krishna BS; Musmade PB; Gautham Shenoy G; Bhat K
Eur J Pharm Sci; 2014 Oct; 62():57-64. PubMed ID: 24878386
[TBL] [Abstract][Full Text] [Related]
8. Differential scanning calorimetry predicts the critical quality attributes of amorphous glibenclamide.
Mah PT; Laaksonen T; Rades T; Peltonen L; Strachan CJ
Eur J Pharm Sci; 2015 Dec; 80():74-81. PubMed ID: 26296864
[TBL] [Abstract][Full Text] [Related]
9. Investigations on the effect of different cooling rates on the stability of amorphous indomethacin.
Karmwar P; Boetker JP; Graeser KA; Strachan CJ; Rantanen J; Rades T
Eur J Pharm Sci; 2011 Oct; 44(3):341-50. PubMed ID: 21884789
[TBL] [Abstract][Full Text] [Related]
10. [Microcosmic mechanisms of amorphous indomethacin crystallization and the influence of nano-coating on crystallization].
Hui OY; Yi T; Zheng Q; Liu F
Yao Xue Xue Bao; 2011 Jun; 46(6):707-12. PubMed ID: 21882533
[TBL] [Abstract][Full Text] [Related]
11. Understanding Dissolution and Crystallization with Imaging: A Surface Point of View.
Novakovic D; Isomäki A; Pleunis B; Fraser-Miller SJ; Peltonen L; Laaksonen T; Strachan CJ
Mol Pharm; 2018 Nov; 15(11):5361-5373. PubMed ID: 30247922
[TBL] [Abstract][Full Text] [Related]
12. Spatial confinement can lead to increased stability of amorphous indomethacin.
Nielsen LH; Keller SS; Gordon KC; Boisen A; Rades T; Müllertz A
Eur J Pharm Biopharm; 2012 Jun; 81(2):418-25. PubMed ID: 22521331
[TBL] [Abstract][Full Text] [Related]
13. Screening for differences in the amorphous state of indomethacin using multivariate visualization.
Savolainen M; Heinz A; Strachan C; Gordon KC; Yliruusi J; Rades T; Sandler N
Eur J Pharm Sci; 2007 Feb; 30(2):113-23. PubMed ID: 17169536
[TBL] [Abstract][Full Text] [Related]
14. Stability of indomethacin with relevance to the release from amorphous solid dispersions studied with ATR-FTIR spectroscopic imaging.
Ewing AV; Clarke GS; Kazarian SG
Eur J Pharm Sci; 2014 Aug; 60():64-71. PubMed ID: 24832964
[TBL] [Abstract][Full Text] [Related]
15. Raman and thermal analysis of indomethacin/PVP solid dispersion enteric microparticles.
Fini A; Cavallari C; Ospitali F
Eur J Pharm Biopharm; 2008 Sep; 70(1):409-20. PubMed ID: 18621516
[TBL] [Abstract][Full Text] [Related]
16. An investigation into the effects of thermal history on the crystallisation behaviour of amorphous paracetamol.
Qi S; Avalle P; Saklatvala R; Craig DQ
Eur J Pharm Biopharm; 2008 May; 69(1):364-71. PubMed ID: 18036792
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of surface crystallisation of amorphous indomethacin particles in physical drug-polymer mixtures.
Priemel PA; Laitinen R; Barthold S; Grohganz H; Lehto VP; Rades T; Strachan CJ
Int J Pharm; 2013 Nov; 456(2):301-6. PubMed ID: 24012867
[TBL] [Abstract][Full Text] [Related]
18. Preparation and characterization of spray-dried co-amorphous drug-amino acid salts.
Jensen KT; Blaabjerg LI; Lenz E; Bohr A; Grohganz H; Kleinebudde P; Rades T; Löbmann K
J Pharm Pharmacol; 2016 May; 68(5):615-24. PubMed ID: 26245703
[TBL] [Abstract][Full Text] [Related]
19. Indomethacin: new polymorphs of an old drug.
Surwase SA; Boetker JP; Saville D; Boyd BJ; Gordon KC; Peltonen L; Strachan CJ
Mol Pharm; 2013 Dec; 10(12):4472-80. PubMed ID: 24025118
[TBL] [Abstract][Full Text] [Related]
20. Physical characterization and stability of amorphous indomethacin and ranitidine hydrochloride binary systems prepared by mechanical activation.
Chieng N; Aaltonen J; Saville D; Rades T
Eur J Pharm Biopharm; 2009 Jan; 71(1):47-54. PubMed ID: 18644443
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]